Presentation, Quarterly Reports, and FDA Approval - Research Report on Merck, United Therapeutics, Endo, Isis Pharmaceuticals,

Presentation, Quarterly Reports, and FDA Approval - Research Report on Merck,
         United Therapeutics, Endo, Isis Pharmaceuticals, and Zogenix

PR Newswire

NEW YORK, November 4, 2013

NEW YORK, November 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Merck &
Co. Inc. (NYSE: MRK), United Therapeutics Corporation (NASDAQ: UTHR), Endo
Health Solutions Inc. (NASDAQ: ENDP), Isis Pharmaceuticals, Inc. (NASDAQ:
ISIS), and Zogenix, Inc. (NASDAQ: ZGNX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Merck & Co. Inc. Research Report

On October 29, 2013, Merck & Co. Inc. (Merck) announced the presentation of
interim data from a Phase 1B trial (PN001) evaluating MK-3475, an
investigational anti-PD-1 immunotherapy, in patients with previously-treated
non-small cell lung cancer (NSCLC). According to Merck, the presentation was
led by Dr. Edward Garon, Director of Thoracic Oncology, Jonsson Comprehensive
Cancer Center, University of California, Los Angeles, at the 15th World
Conference on Lung Cancer in Sydney, Australia. Dr. Eric H. Rubin, Vice
President, Oncology, Merck Research Laboratories, stated, "Based on these
preliminary data and other research, we believe that PD-L1 expression has the
potential to be a useful predictor of response to MK-3475 in certain cancers.
We look forward to further data from this and other studies to help us to
understand the potential role of MK-3475 in lung cancer, and of PD-L1 as a
biomarker." The Full Research Report on Merck & Co. Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/430d_MRK]

United Therapeutics Corporation Research Report

On October 29, 2013, United Therapeutics Corporation (United Therapeutics)
released its Q3 2013 results. United Therapeutics registered total revenues of
$302.2 million in Q3 2013, up 24.6% YoY. The Company posted net income of
$62.7 million in Q3 2013, down compared to net income of $78.1 million in Q3
2012. United Therapeutics reported diluted EPS of $1.17 in Q3 2013, compared
to diluted EPS of $1.46 in Q3 2012. Commenting on the results, Martine
Rothblatt, Ph.D., United Therapeutics' Chairman and CEO, said, "I am extremely
pleased with the results of the third quarter." Rothblatt continued, "Our
medicines are now prescribed for more PAH patients in the United States than
any other company." The Full Research Report on United Therapeutics
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/e4cc_UTHR]

Endo Health Solutions Inc. Research Report

On October 29, 2013, Endo Health Solutions Inc. (Endo) announced that it will
release its Q3 2013 results before the US financial markets open on Thursday,
November 7, 2013. Endo reported that the release will be followed by its Q3
2013 conference call at 8:00 a.m. ET, which will be hosted by its senior
management. The Company further informed that there will be a simultaneous
webcast of the conference call on its website, whereas an archived version of
the webcast will be available until 11:59 p.m. ET on Thursday, November 21,
2013 in the Events section on its Investor Relations website. Endo stated that
the. The Full Research Report on Endo Health Solutions Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/059c_ENDP]

Isis Pharmaceuticals, Inc. Research Report

On October 29, 2013, Isis Pharmaceuticals, Inc. (Isis) announced that it will
host its Q3 2013 conference call on Tuesday, November 5, 2013 at 11:30 a.m. ET
/ 8:30 a.m. PT. Isis reported that the call will be webcast live on the
Internet through its website. The Company informed that a webcast replay will
be also available for a limited time on its website. The Full Research Report
on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/fcfc_ISIS]

Zogenix, Inc. Research Report

On October 25, 2013, Zogenix, Inc. (Zogenix) announced that the US Food and
Drug Administration (FDA) has approved Zohydro ER (hydrocodone bitartrate)
extended-release capsules. According to Zogenix, Zohydro ER is an opioid
agonist, extended-release oral formulation of hydrocodone without
acetaminophen, for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative
treatment options are inadequate. Zogenix reported that it expects to launch
Zohydro ER in approximately four months. The Full Research Report on Zogenix,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/ef36_ZGNX]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.